Last updated on July 2019

INCB 18424-272 A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who are Resistant to or Intolerant of Hydroxyurea


Brief description of study

INCB 18424-272 A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who are Resistant to or Intolerant of Hydroxyurea

Detailed Study Description

Ruxolitinib (previously known as INCB018424 phosphate, INC424, ruxolitinib phosphate) is a novel, potent, and selective inhibitor of Janus kinase (JAK) 1 and JAK2 with modest to marked selectivity against tyrosine kinase 2 (TYK2) and JAK3, respectively. Ruxolitinib has been granted marketing authorisation approval for the treatment of myelofibrosis (MF) and polycythemia vera (PV) and is currently in development for the treatment of myeloproliferative neoplasms (MPNs; MF, PV, and essential thrombocythemia [ET]) and other hematologic malignancies.

Clinical Study Identifier: TX153063

Find a site near you

Start Over

Baptist Health Lexington Clinical Research Center

1740 Nicholasville Road Lexington, KY USA
  Connect »